

Executive update to the Board

May 2026

Summary

- Since our last meeting, we have published several pieces of notable guidance. Examples include:
 - ✓ **More than a million people** will have access to weekly semaglutide injections to help prevent both heart attacks and strokes – which remain one of the leading causes of early death and ill health in England.
 - ✓ NICE has recommended rozanolixizumab, the **first treatment for people with myasthenia gravis** in England.
 - ✓ We have recommended five new AI tools, which could **save lives by spotting signs of bowel cancer earlier** in colonoscopies.
 - ✓ Our guidelines are supporting **the new Women's Health Strategy**, with updates to support earlier diagnosis of ovarian cancer and an update to our fertility guidelines to recognise the needs of people with endometriosis.
 - ✓ We have published our first guideline and quality standard on kidney cancer covering diagnosis and management. It includes infographics incorporating all technology appraisals for kidney cancer into a pathway of care – **making it easier for clinical users to implement** this guidance.
- **We continue to deliver our work programme: 70% of KPIs in our Integrated Performance Report (IPR) are "green" and we have delivered on our 10 Year Plan milestones for 2025/26.** Key milestones that have been met include:
 - ✓ Launched the new aligned pathway between NICE and the MHRA, which will bring medicines to patients 3-6 months faster. Over 40% of NICE's topics are already scheduled to this pathway. Alongside this, we have launched our MHRA – NICE Integrated Advice Service, which will offer a single-entry point, payment and advice meeting with our users. The Integrated Advice Service has been designed to help companies follow aligned pathway timelines.
 - ✓ Implemented NICE's new cost-effectiveness thresholds for the Technology Appraisal programme and commenced a public consultation on our proposed adoption of the new EQ-5D-5L value set for measuring health states in NICE appraisals.
- We will build on these successes in 2026/27. This will be discussed in a dedicated item on the 2026/27 Business Plan.